Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity

• Main Authors: Mohammad Hossein Ataee (Author), Seyed Ali Mirhosseini (Author), Reza Mirnejad (Author), Ehsan Rezaie (Author), Hamideh Mahmoodzadeh Hosseini (Author), Jafar Amani (Author)
• Format: Book
• Published: Wolters Kluwer Medknow Publications, 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background and purpose: The lack of a new effective treatment for small cell lung cancer (SCLC) is an unresolved problem. Due to the new identification of delta-like ligand 3 (DLL3) and its high expression in SCLC patients, the use of DLL3 in target therapy can be effective. The use of bacterial tox...